Skip to main content

Table 2 Cost (USD at 2018 levels) per QALY by drug price and PrEP Efficacy

From: Cost utility analysis of HIV pre exposure prophylaxis among men who have sex with men in Israel

PrEP Efficacy
Price(a)(b)(c)(d)(e)(f)
Decrease56.3%70.0%78.5%86.0%90.0%97.1%
10%2,689,6031,521,8351,174,811967,744881,831754,449
25%2,301,8191,290,388989,823810,477736,066625,738
50%1,655,511904,643681,509548,366493,124411,218
70%1,138,465596,047434,858338,677298,771239,603
90%621,419287,451188,206128,988104,41767,988
  1. (a) Current baseline estimate
  2. (b) lower 90%/95% bounds from refs [2, 4, 5]
  3. (c) weighted average from refs [2, 4, 5]
  4. (d) weighted average from refs [4, 5] (baseline)
  5. (e) upper 90%/95% bounds from [2, 4, 5]
  6. (f) ref. [10]
  7. Assumes background decline in HIV for four more years, 80% PrEP take up by high-risk MSM,
  8. 25% PrEP take up by low-risk MSM of whom 75% stop condom use
  9. Based on MOH payment schedule to HMOs for HIV/AIDS patients